Should we continue to offer consolidative radiation for early stage, non-bulky Hodgkin's disease for individuals who have had a complete response (Deauville 1 or 2) after chemotherapy by PET?

The RAPID study was a non-inferiority trial. This requires a small editorial. Non-inferiority trials are designed to test that one approach is "not worse" than an accepted standard. However, in essence you are testing that one approach is "not unacceptably worse" than an accepted standard, because t...